Synthetic Biologics Forum: Community User: Fee

https://www.globenewswire.com/news-release/2023/01/17/2589893/0/en/Theriva-Biologics-Announces-First-Patient-Dosed-in-VIRAGE-a-Phase-2b-Trial-of-Systemically-Administered-VCN-01-in-Combination-with-Chemotherapy-in-Pancreatic-Ductal-Adenocarcinoma.html

https://www.globenewswire.com/news-release/2023/01/09/2585174/0/en/Theriva-Biologics-Announces-Dosing-of-First-Patient-in-the-Investigator-Sponsored-Phase-1-Trial-of-VCN-01-an-Intravenous-Oncolytic-Adenovirus-in-Patients-with-Brain-Tumors.html

Theriva Biologics Reports Third Quarter 2022 Operational Highlights and Financial Results https://www.globenewswire.com/news-release/2022/11/10/2553867/0/en/Theriva-Biologics-Reports-Third-Quarter-2022-Operational-Highlights-and-Financial-Results.html –Reported encouraging clinical data supporting the differentiated mode-of action of Theriva’s novel oncolytic adenovirus (OV) platform– –Received clearance from the Federal Drug Administration (FDA) and Spanish Competent Authority (AEMPS) for the planned Phase 2 clinical trial of systemically administered VCN-01 in Pancreatic Ductal Adenocarcinoma (PDAC) patients– –Reported positive safety and pharmacokinetic data from Cohort 1 of the Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant recipients and dosed the first patient in Cohort 2– –As of September 30, 2022, Theriva Biologics reports $50.5 million in cash, which is expected to provide runway into the first quarter of 2024–

https://www.globenewswire.com/news-release/2022/11/03/2547572/0/en/Theriva-Biologics-Announces-First-Patient-Dosed-in-Second-Cohort-of-Phase-1b-2a-Clinical-Trial-of-SYN-004-ribaxamase-in-Allogeneic-Hematopoietic-Cell-Transplant-Recipients.html

Theriva Biologics Announces Presentation at the 14th International Oncolytic Virotherapy (IVOC) Conference Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck https://stockhouse.com/news/press-releases/2022/10/24/theriva-biologics-announces-presentation-at-the-14th-international-oncolytic - Data to be featured in an oral presentation highlighting the encouraging biological activity of VCN-01 treatment in combination with durvalumab-

Synthetic Biologics Rebrands as Theriva Biologics https://www.globenewswire.com/news-release/2022/10/12/2532817/0/en/Synthetic-Biologics-Rebrands-as-Theriva-Biologics.html Rebrand solidifies sharpened clinical development strategy to advance unique oncolytic viruses optimized for intravenous (IV) administration ... In addition, the Company announced its common stock is expected to begin trading on NYSE American under the new ticker symbol “TOVX” on Thursday, October 13, 2022. ...

Synthetic Biologics gibt positives Ergebnis der Überprüfung durch das Data and Safety Monitoring Committee (DSMC) in der klinischen Phase 1b/2a-Studie mit SYN-004 (Ribaxamase) bei Empfängern von allogenen hämatopoetischen Zelltransplantaten bekannt

https://twitter.com/PatentGrants/status/1569700636505296901

"Synthetic Biologics has received a Notice of Allowance for its US patent application 17/314,583 titled 'E. COLI-BASED PRODUCTION OF BETA-LACTAMASE (FOR MICROBIOME-PROTECTING THERAPY)'. Recent reverse split."  https://www.benzinga.com/general/biotech/22/09/28850608/synthetic-biologics-has-received-a-notice-of-allowance-for-its-us-patent-application-17314-583-ti

https://www.marketscreener.com/quote/stock/SYNTHETIC-BIOLOGICS-INC-45286486/news/SYNTHETIC-BIOLOGICS-INC-Other-Events-Financial-Statements-and-Exhibits-form-8-K-41753006/

https://www.globenewswire.com/news-release/2022/09/05/2509716/0/en/Synthetic-Biologics-Announces-Presentation-at-ESMO-Congress-2022-Describing-Phase-1-Investigator-sponsored-Study-Evaluating-VCN-01-in-Combination-with-Durvalumab-in-Patients-with-R.html

Hoffentlich kommt da nochmal was

...bin auch eingestiegen, Fee

;-)

Die 2 haben wir schon mal 😂